NCT05416411

Brief Summary

Postoperative pulmonary complications (PPCs) are the most frequent complications occurring in patients undergoing thoracic surgery and they are associated with prolonged hospital stay, decreased survival and expanding medical costs. Implementation of structured and supervised exercise programs including endurance training (ET), respiratory muscle training (RMT) or a combination of both, within the short waiting period before surgery, has been shown to enhance patients' physical fitness, to provide protective effects against PPCs and therefore to spare health care resources by shortening intensive care unit (ICU) and hospital lengths of stay. More recently, a simple intervention consisting in patient's instruction and education about modifiable risk factors, optimal breathing pattern and the impact of physical exercise has emerged as a simple alternative intervention prevent PPCs, although the evidence is inconclusive. Therefore, the investigators propose a multicentre randomized, open, blinded end point controlled trial testing the hypothesis that preoperative education and instruction focused on breathing exercise and endurance training reduce the occurrence of PPCs in patients undergoing thoracic or abdominal surgery. Patients with Intermediate-to-high risks factors for PPCs will be randomized on a 1:1 basis into an intervention arm and a usual care arm (Control group). In the Education group, patients will be asked to use a flow resistive device (One set of 30 repetitions, two times a day and to increase their daily physical activities (\> 5'000 steps or equivalent) until surgery. Primary study endpoint will be the incidence of PPCs (e.g., atelectasis, pneumonia, respiratory failure) according to the European Perioperative Clinical Outcome definitions. Secondary outcomes will include non-respiratory complications, utilization of hospital resources (e.g., hospital length of stay, ICU admission),and preoperative changes in maximal inspiratory pressure \[MIP\]. Assuming a rate of 39% PPCs in the controls and a possible reduction to 26% in the intervention group, enrollment of 203 patients per group will provide 80% power with an alpha value of 0.05. Taking into account dropouts (5%) and in-hospital mortality rate (2%), a total of 436 surgical patients will be enrolled.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
436

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2022

Typical duration for not_applicable

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 8, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 13, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

July 20, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 10, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 10, 2024

Completed
Last Updated

December 27, 2023

Status Verified

December 1, 2023

Enrollment Period

2 years

First QC Date

June 8, 2022

Last Update Submit

December 23, 2023

Conditions

Keywords

prehabilitation

Outcome Measures

Primary Outcomes (1)

  • The incidence of postoperative pulmonary complications

    Postoperative pulmonary complications will be investigated during the postoperative 5 days. These complications are named according to the European Perioperative Clinical Outcome (EPCO) definitions (Respiratory failure, aspiration pneumonitis, pneumonia, ARDS, pneumothorax, atelectasis, bronchospasm)

    Up to postoperative 5 days

Secondary Outcomes (5)

  • Preoperative MIP change

    7 days

  • Length of stay in hospital

    Up to 15 days

  • Visual Analog Scale thoracic rest pain

    Up to 5 days

  • Visual Analog Scale thoracic coughing pain

    Up to 5 days

  • Visual Analog Scale dyspnea

    Up to 5 days

Study Arms (2)

Usual Care

NO INTERVENTION

Patients who are candidates for thoracic resection surgeries will be advised to stay active and quit smoking.

Intervention group

ACTIVE COMPARATOR

Patients who are candidates for thoracic resection surgeries will be handed a flow resistive device that helps inspiratory muscle training (2\*30 repetitions a day for 7 days) and will be advised to walk 5000 steps a day.

Behavioral: Inspiratory muscle training

Interventions

Patients will do inspiratory muscle training via a flow resistive device. Priorly, maximum inspiratory pressure will be measured. Afterwards, the training device will be set to 10% increased value of maximum inspiratory pressure (MIP), and the training will be completed two times and 30 repetitions a day during preoperative 7 days. Meanwhile patients will be advised to walk 5000 steps a day during the intervention period.

Also known as: Walking (5000 steps/day)
Intervention group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients (\> 18 years)
  • Risk factors for PPCs (ARISCAT score \>27)
  • Elective intra-abdominal surgery or intrathoracic surgery via an open or minimally-invasive approach, expected to last \> 120 min.

You may not qualify if:

  • Patients unable to understand the instructions and/or to perform the proposed training program (i.e., poor comprehension, chest pain)
  • COPD GOLD Grade III and IV, lung fibrosis, documented bullae, severe emphysema, pneumothorax
  • Patient with chest pain or at risk of pneumothorax
  • Previous lung surgery
  • Bilateral lung procedures
  • Emergent surgery or organ transplant
  • Planned mechanical ventilation after surgery
  • Uncontrolled asthma
  • Coronary heart disease with angina grade 3 or 4 Canadian Cardiovascular Society
  • documented pulmonary arterial hypertension \>25mmHg mean pulmonary arterial pressure (PAP) at rest or \> 40 mmHg systolic PAP (estimated by ultrasound)
  • Documented or suspected neuromuscular disease (thymoma, myasthenia, myopathies, muscular dystrophies, others)
  • Intracranial injury or tumor
  • Persistent hemodynamnic instability, intractable shock
  • Pregnancy (excluded by anamnesis and/or laboratory analysis)
  • Enrollment in another interventional study or refusal of informed consent
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Acıbadem Mehmet Ali Aydınlar University, Faculty of Medicine

Istanbul, Turkey (Türkiye)

RECRUITING

Istanbul University Istanbul Faculty of Medicine

Istanbul, Turkey (Türkiye)

RECRUITING

Koc University, Faculty of Medicine

Istanbul, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Postoperative Complications

Interventions

Walking

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

LocomotionMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaExerciseMotor Activity

Study Officials

  • Emre S Bingul, MD

    Istanbul University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor, Lecturer

Study Record Dates

First Submitted

June 8, 2022

First Posted

June 13, 2022

Study Start

July 20, 2022

Primary Completion

July 10, 2024

Study Completion

July 10, 2024

Last Updated

December 27, 2023

Record last verified: 2023-12

Locations